Carboplatin/Etoposide/VismodegibLack of efficacy: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2032卷 / 1期

关键词：

D O I：

10.1007/s40278-024-69772-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：111 / 111

相关论文

共 50 条

[21] VismodegibLack of efficacy: case report
Reactions Weekly, 2023, 1940 (1) : 402 - 402
[22] VismodegibLack of efficacy: case report
Reactions Weekly, 2022, 1897 (1) : 352 - 352
[23] VismodegibLack of efficacy: case report
Reactions Weekly, 2024, 2024 (1) : 425 - 425
[24] Carboplatin/etoposide/toripalimabLack of efficacy and hypophysitis: case report
Reactions Weekly, 2023, 1957 (1) : 119 - 119
[25] Denosumab/vismodegibLack of efficacy: case report
Reactions Weekly, 2022, 1933 (1) : 176 - 176
[26] Carboplatin/etoposide/gefitinibAcquired resistance and lack of efficacy: case report
Reactions Weekly, 2023, 1945 (1) : 150 - 150
[27] Carboplatin/etoposide/immune-globulinLack of efficacy: case report
Reactions Weekly, 2025, 2051 (1) : 81 - 81
[28] Carboplatin/Etoposide/IfosfamideLack of efficacy and drug intolerance : case report
Reactions Weekly, 2024, 2034 (1) : 93 - 93
[29] Carboplatin/etoposide/serplulimabGastrointestinal reactions and lack of efficacy: case report
Reactions Weekly, 2024, 2037 (1) : 104 - 104
[30] Carboplatin/etoposide/meropenemFulminant amoebic colitis and lack of efficacy: case report
Reactions Weekly, 2021, 1886 (1) : 119 - 119

← 1 2 3 4 5 →